...
首页> 外文期刊>American journal of therapeutics >A Simple Dose Regimen of Artesunate and Amodiaquine Based on Age or Body Weight Range for Uncomplicated Falciparum Malaria in Children: Comparison of Therapeutic Efficacy With Standard Dose Regimen of Artesunate and Amodiaquine and Artemether-Lumefantrine
【24h】

A Simple Dose Regimen of Artesunate and Amodiaquine Based on Age or Body Weight Range for Uncomplicated Falciparum Malaria in Children: Comparison of Therapeutic Efficacy With Standard Dose Regimen of Artesunate and Amodiaquine and Artemether-Lumefantrine

机译:基于年龄或体重范围的儿童单纯性恶性疟疾青蒿琥酯和阿莫地喹的简单剂量方案:青蒿琥酯和阿莫地喹标准剂量方案与蒿甲醚-卢美替宁的治疗效果比较

获取原文
获取原文并翻译 | 示例
           

摘要

A new dose regimen of artesunate and amodiaquine (NDRAA) based on age or body weight range was compared with standard dose regimen of artesunate and amodiaquine (SDRAA) calculated according to body weight and with fixed-dose artesunate-amodiaquine (FDAA) and artemether-lumefantrine (AL) in 304 children afflicted by malaria aged 15 years or younger. In initial comparison (n = 208), children on NDRAA received 1-3 times amodiaquine per kilogram of body weight and 1-1.5 times of artesunate per kilogram of body weight compared with those receiving SDRAA. Parasite but not fever clearance was significantly faster in children who received NDRAA (19.4 6 8.4 hours vs. 24.6 6 15.5 hours, P = 0.003). Polymerase chain reaction-uncorrected cure rates on days 28-42 were also significantly higher in children who received NDRAA (P < 0.02 in all cases). Therapeutic responses in children younger than 5 years (n = 96) treated with NDRAA, FDAA, and AL were similar. Changes in hematocrit values and reported adverse events after commencing therapy were similar in those who received NDRAA and SDRAA.
机译:比较了根据年龄或体重范围确定的新剂量青蒿琥酯和阿莫地喹(NDRAA)与根据体重计算的青蒿琥酯和阿莫地喹标准剂量方案(SDRAA)以及固定剂量青蒿琥酯-阿莫地喹(FDAA)和蒿甲醚- 304名15岁以下的疟疾患儿中的lumantantrine(AL)。在最初的比较中(n = 208),与接受SDRAA的儿童相比,接受NDRAA的儿童每公斤体重接受1-3倍的阿莫地喹和每公斤体重1-1.5倍的青蒿琥酯。接受NDRAA的儿童中的寄生虫清除而非发烧清除速度明显加快(分别为19.4 6 8.4小时和24.6 6 15.5小时,P = 0.003)。在接受NDRAA治疗的儿童中,未校正的聚合酶链反应治愈率在第28-42天也显着更高(在所有情况下,P <0.02)。用NDRAA,FDAA和AL治疗的5岁以下儿童(n = 96)的治疗反应相似。接受NDRAA和SDRAA治疗的患者开始治疗后血细胞比容值的变化和不良事件的报告相似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号